Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas. Show more

Location: 1017 Ranch Road 620 South, Lakeway, TX, 78734, United States | Website: https://www.anebulo.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

95.73M

52 Wk Range

$0.80 - $3.42

Previous Close

$2.33

Open

$2.37

Volume

1,111

Day Range

$2.26 - $2.37

Enterprise Value

85.37M

Cash

10.35M

Avg Qtr Burn

-1.483M

Insider Ownership

40.54%

Institutional Own.

54.08%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Selonabant (ANEB-001) Details Cannabinoid intoxication	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IV Selonabant (ANEB-001) Details Cannabinoid intoxication	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.